- Life Sciences
- Conference
RAS-Targeted Drug Development Summit
Tempus is advancing precision medicine through the practical application of artificial intelligence in healthcare. We are pleased to attend this conference and present on how Tempus can support your needs.
Multimodal Real-World Data for Accelerating Translational Research & De-Risking KRAS Drug Development
The recent development of KRAS G12C inhibitors underscores the potential to target additional KRAS variants and develop combination therapeutic strategies Harmonized multimodal data sources can help KRAS researchers: Identify co-alterations and other biomarkers associated with response Identify co-alterations and other biomarkers associated with response Select the most appropriate patient populations to enroll in clinical studies Validate clinical trial designs Data-driven approach to KRAS-targeted drug development will continue to help biopharma organizations bring these important treatments to patients faster and at a lower cost
Kathleen Burke Director of Computational Biology, Pharma R&D
Learn more↗Schedule a meeting with us
We'll be in touch shortly.